Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney-Reference-Cited by-同舟云学术

Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney

Published:2021-07-03 Issue: Volume: Page:
ISSN:0007-1188
Container-title:British Journal of Pharmacology
language:en
Short-container-title:British J Pharmacology

Author:

Stehle Daniel¹^ORCID,Xu Min Ze²,Schomber Tibor³,Hahn Michael G.³,Schweda Frank⁴,Feil Susanne¹,Kraehling Jan R.³,Eitner Frank³⁵,Patzak Andreas²,Sandner Peter³⁶^ORCID,Feil Robert¹^ORCID,Bénardeau Agnès³⁷

Affiliation:

1. Interfakultäres Institut für Biochemie (IFIB) University of Tübingen Tübingen Germany

2. Institute of Vegetative Physiology Charité‐Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt‐Universität zu Berlin Berlin Germany

3. Bayer AG, Cardiovascular Research Pharma Research Center Wuppertal Germany

4. Institut für Physiologie Universität Regensburg Regensburg Germany

5. Division of Nephrology and Clinical Immunology RWTH Aachen University Aachen Germany

6. Institute of Pharmacology Hannover Medical School Hannover Germany

7. Novo Nordisk A/S Cardio‐Renal Biology Måløv Denmark

Publisher

Wiley

Subject

Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bph.15586

Reference54 articles.

1. The Concise Guide to PHARMACOLOGY 2019/20: Catalytic receptors;Alexander S. P. H.;British Journal of Pharmacology,2019

2. The novel soluble guanylyl cyclase (sGC) activator runcaciguat induced renal vasodilation and attenuated kidney damage in a rat CKD model;Benardeau A.;Journal of the American Society of Nephrology,2020

3. A Soluble Guanylate Cyclase Activator Inhibits the Progression of Diabetic Nephropathy in the ZSF1 Rat

4. Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy

5. Developing Treatments for Chronic Kidney Disease in the 21st Century

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Renal arterial resistance index before and after vericiguat administration: Should it be considered the fantastic five?;International Journal of Cardiology;2024-11

2. Assessment of adverse events of the novel cardiovascular drug vericiguat: a real-world pharmacovigilance study based on FAERS;Expert Opinion on Drug Safety;2024-07-19

3. Effect of Avenciguat on Albuminuria in Patients with CKD;Journal of the American Society of Nephrology;2024-05-25

4. Renal Arterial Resistance Index Before and after Vericiguat Administration: Should it Be Considered the Fantastic Five?;2024

5. Soluble guanylyl cyclase: A novel target for the treatment of vascular cognitive impairment?;Pharmacological Research;2023-11